Indomethacin 25 MG/50 MG
DrugA 50 mg indomethacin suppository will be administered rectally 30 minutes before hysterosalpingography.
NCT Number: NCT07792668
Hysterosalpingography (HSG) is commonly performed during infertility evaluation and may cause pain during cervical manipulation, uterine distension, and contrast-medium injection. This prospective, randomized, three-arm controlled trial will compare three pain-control approaches during HSG: no analgesic premedication, rectal indomethacin administered before the procedure, and paracervical block with lidocaine. Eligible women scheduled for diagnostic HSG will be randomized in a 1:1:1 ratio. The primary outcome will be participant-reported pain during contrast-medium injection measured using an 11-point Numeric Rating Scale (NRS) ranging from 0 to 10. Secondary outcomes will include pain during other procedural stages, immediate and 30-minute post-procedural pain, preprocedural anxiety, anticipated pain, rescue analgesic requirement, participant satisfaction, and adverse events.
Trial opening soon.
Get Notified18 year–45 year
Female
Interventional
Phase 3
Hysterosalpingography is an established diagnostic procedure used to assess tubal patency and uterine cavity morphology during infertility evaluation. Pain may occur at several procedural stages, including speculum insertion, cervical grasping, cannula placement, cervical traction, uterine distension, and contrast-medium injection.
This study is designed as a prospective, randomized, parallel-group, three-arm controlled superiority trial. Participants will be allocated in a 1:1:1 ratio to no premedication, rectal indomethacin, or paracervical block with lidocaine.
Pain intensity will be assessed using an 11-point Numeric Rating Scale ranging from 0, indicating no pain, to 10, indicating the worst imaginable pain. The primary outcome is pain during contrast-medium injection. Additional procedural pain scores, immediate post-procedural pain, pain at 30 minutes, preprocedural anxiety, anticipated pain, participant satisfaction, requirement for rescue analgesia, and adverse events will also be recorded.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A 50 mg indomethacin suppository will be administered rectally 30 minutes before hysterosalpingography.
A paracervical block will be performed using 2% lidocaine. Five milliliters of 2% lidocaine will be administered at the 4 o'clock position and 5 mL at the 8 o'clock position of the cervix, for a total volume of 10 mL and a total lidocaine dose of 200 mg. Injection depth will be approximately 1.5 to 3 cm. Hysterosalpingography will begin 5 minutes after completion of the paracervical block.
Time frame: During HSG, immediately after contrast-medium injection
Participant-reported pain intensity will be measured using an 11-point Numeric Rating Scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity.
Time frame: During HSG, immediately after speculum insertion
Pain intensity measured using an 11-point NRS ranging from 0 to 10.
Time frame: During HSG, immediately after tenaculum application or cervical grasping
Pain intensity measured using an 11-point NRS ranging from 0 to 10.
Time frame: During HSG, immediately after cannula or catheter placement
Pain intensity measured using an 11-point NRS ranging from 0 to 10.
Time frame: During HSG, immediately after cervical traction
Pain intensity measured using an 11-point NRS ranging from 0 to 10.
Time frame: Within 5 minutes after completion of HSG
Pain intensity measured using an 11-point NRS ranging from 0 to 10.
Time frame: 30 minutes after completion of HSG
Pain intensity measured using an 11-point NRS ranging from 0 to 10.
Time frame: After informed consent and before randomization and administration of the study intervention
Preprocedural state anxiety measured using the validated Turkish five-item short version of the State Anxiety Inventory (STAIS-5). Higher scores indicate greater state anxiety.
Time frame: Before randomization and administration of the study intervention.
Expected pain during HSG measured using a single 0-to-10 Numeric Rating Scale.
Time frame: Immediately after HSG.
Participant-reported satisfaction with pain control measured using a 0-to-10 scale, with higher scores indicating greater satisfaction.
Time frame: From completion of HSG through 30 minutes after the procedure
Number/percentage requiring additional analgesia.
Time frame: From administration of the study intervention through 30 minutes after HSG
Nausea, vomiting, dizziness, vasovagal symptoms, allergic symptoms, rectal discomfort, injection-site bleeding/hematoma, severe cramping, etc.
Time frame: Immediately after HSG
Participant-reported most painful step during HSG.
Contact information is provided by the study sponsor or research team.
Balikesir University
Other
Comparison of No Premedication, Rectal Indomethacin Suppository, and Paracervical Block for Pain Reduction During Hysterosalpingography: A Prospective Randomized Three-Arm Controlled Trial
Acronym: HSG-PAIN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07773337
Adnexal Diseases, Anovulation
Diyarbakır, Turkey (Türkiye)
View Trial DetailsNCT07738068
Female Infertility, Female Urogenital Diseases
View Trial DetailsNCT07725458
Behavior, Genital Diseases
Tampa, Florida, United States
View Trial DetailsNCT07691073
Genital Diseases, Infertility
Sabadell, Barcelona, Spain
View Trial Details